Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
OBJECTIVE
Both dose-escalated external beam radiotherapy (DE-EBRT) and androgen deprivation therapy (ADT) improve outcomes in patients with high-risk prostate cancer. However, there is little evidence specifically evaluating DE-EBRT for patients with high-risk prostate cancer receiving ADT, particularly for EBRT doses >74 Gy. We aimed to determine whether DE-EBRT >74 Gy improves outcomes for patients with high-risk prostate cancer receiving long-term ADT.


METHODS
Patients with high-risk prostate cancer were treated on an institutional protocol prescribing 3-6 months neoadjuvant ADT and DE-EBRT, followed by 2 years of adjuvant ADT. Between 2006 and 2012, EBRT doses were escalated from 74 Gy to 76 Gy and then to 78 Gy. We interrogated our electronic medical record to identify these patients and analyzed our results by comparing dose levels.


RESULTS
In all, 479 patients were treated with a 68-month median follow-up. The 5-year biochemical disease-free survivals for the 74 Gy, 76 Gy, and 78 Gy groups were 87.8%, 86.9%, and 91.6%, respectively. The metastasis-free survivals were 95.5%, 94.5%, and 93.9%, respectively, and the prostate cancer-specific survivals were 100%, 94.4%, and 98.1%, respectively. Dose escalation had no impact on any outcome in either univariate or multivariate analysis.


CONCLUSIONS
There was no benefit of DE-EBRT >74 Gy in our cohort of high-risk prostate patients treated with long-term ADT. As dose escalation has higher risks of radiotherapy-induced toxicity, it may be feasible to omit dose escalation beyond 74 Gy in this group of patients. Randomized studies evaluating dose escalation for high-risk patients receiving ADT should be considered.
Department of Radiation Oncology, North Coast Cancer Institute, University of New South Wales, Coffs Harbour, NSW, Australia; Rural Clinical School, Faculty of Medicine, University of New South Wales, Coffs Harbour, NSW, Australia.
Thomas P
TP
Shakespeare
Department of Radiation Oncology, North Coast Cancer Institute, University of New South Wales, Coffs Harbour, NSW, Australia.
Shea W
SW
Wilcox
Department of Radiation Oncology, North Coast Cancer Institute, University of New South Wales, Coffs Harbour, NSW, Australia; Rural Clinical School, Faculty of Medicine, University of New South Wales, Coffs Harbour, NSW, Australia.
Noel J
NJ
Aherne
IMRT; androgen deprivation therapy; dose; dose de-escalation; dose escalation; prostate cancer; radiotherapy